Sentynl Therapeutics - About the company
Sentynl Therapeutics is an acquired company based in San Diego (United States), founded in 2011 by David Preston and Matthew Heck. It operates as a Developer of novel biopharmaceutical medicines for rare diseases. The company has 1054 active competitors, including 30 funded and 290 that have exited. Its top competitors include companies like Teva Pharmaceuticals, The Alvogen and Laboratorio Reig Jofre.
Company Details
Developer of novel biopharmaceutical medicines for rare diseases. It focuses on providing medicines that extend, improve, or enhance the lives of patients. The company's guiding principles emphasize impact, innovation, and integrity in its approach to developing and delivering these treatments. A commitment to addressing unmet medical needs is central to its mission.
- Website
- sentynl.com
- Social
- Email ID
- *****@sentynl.com
Key Metrics
Founded Year
2011
Location
San Diego, United States
Stage
Acquired
Investors
Ranked
112th among 1054 active competitors
Employee Count
27 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Acquired by Zydus Life (Jan 19, 2017)
Sentynl Therapeutics's acquisition details
Sentynl Therapeutics got acquired by Zydus Life on Jan 19, 2017.
Click here to take a look at Sentynl Therapeutics's acquisition in detail
Sign up to download Sentynl Therapeutics' company profile
Sentynl Therapeutics's funding and investors
Sentynl Therapeutics is a funded company. Sentynl Therapeutics has 1 institutional investor.
View details of Sentynl Therapeutics's funding rounds and investors
Sentynl Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Sentynl Therapeutics are David Preston and Matthew Heck.
Here are the details of Sentynl Therapeutics' key team members:
- David Preston: Co-Founder & COO of Sentynl Therapeutics. They serve on the board of 1 company.
- Matthew Heck: Co-Founder & CEO of Sentynl Therapeutics and founder of 1 other company.
View details of Sentynl Therapeutics's Founder profiles and Board Members
Sentynl Therapeutics' employee count trend
Sentynl Therapeutics has 27 employees as of Sep 26. Here is Sentynl Therapeutics's employee count trend over the years:
Uncover Sentynl Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Sentynl Therapeutics's Competitors and alternates
Top competitors of Sentynl Therapeutics include Teva Pharmaceuticals, The Alvogen and Laboratorio Reig Jofre. Here is the list of Top 10 competitors of Sentynl Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Teva Pharmaceuticals 1901, Petah Tikva (Israel), Public | Traditional company engaged in manufacturing generics | $500M | 75/100 | |
2nd | The Alvogen 2009, Morristown (United States), Acquired | Developer and marketer of pharmaceutical products | $156M | 69/100 | |
3rd | Laboratorio Reig Jofre 2000, Barcelona (Spain), Public | Manufacturer of pharmaceutical products and food supplements | - | 68/100 | |
4th |  Hikma Pharmaceuticals 1978, London (United Kingdom), Public | Manufacturer of generic medicines and injectable pharmaceutical products for patients | - | 67/100 | |
5th | ANI Pharmaceuticals 1996, Baudette (United States), Public | Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets | - | 66/100 | |
6th | Manufacturer of generic pharmaceuticals and nutraceuticals | - | 66/100 | ||
7th | Large diversified pharma company | - | 66/100 | ||
8th |  Bausch & Lomb 1853, Bridgewater (United States), Public | Manufacturer of prescription pharmaceutical products and various eye care items | - | 65/100 | |
9th | Developer and manufacturer of branded and generic pharmaceutical products | - | - | 64/100 | |
10th | Inventia Healthcare 1985, Mumbai (India), Acquired | Manufacturer & developer of various oral solid oral drug delivery systems | $42.5M | 63/100 | |
112th | Sentynl Therapeutics 2011, San Diego (United States), Acquired | Developer of novel biopharmaceutical medicines for rare diseases | - | 47/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Sentynl Therapeutics's competitors? Click here to see the top ones
Sentynl Therapeutics's Investments and acquisitions
Sentynl Therapeutics has acquired Zokinvy. Sentynl Therapeutics has not made any investments as of now.Reports related to Sentynl Therapeutics
Here is the latest report on Sentynl Therapeutics's geography:
News related to Sentynl Therapeutics
Filter this listMedia has covered Sentynl Therapeutics for a total of 7 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
Zydus arm Sentynl secures US rights option for rare lung disease drugCNBC-TV18•Aug 11, 2026•Sentynl Therapeutics, Zydus Life, Mereo
•
Sentynl and PRG partner for Progerinin licenceHospital Management•Mar 17, 2026•PRG S&Tech, Sentynl Therapeutics
•
Zydus entity Sentynl’s drug for Menkes disease gets U.S. FDA nodThe Hindu•Jan 13, 2026•Sentynl Therapeutics
•
Sentynl Therapeutics Receives FDA Acceptance for CUTX-101 NDA, target date January 14, 2026PR Newswire•Dec 15, 2025•Sentynl Therapeutics
•
FDA accepts Sentynl’s Menkes disease therapy NDA for priority reviewPharmaceutical Technology•Jan 07, 2025•Sentynl Therapeutics
•
Sentynl Therapeutics Receives Great Place To Work® CertificationPR Newswire•Jun 03, 2024•Sentynl Therapeutics
•
Sentynl Therapeutics, A Zydus Company Acquires Zokinvy For Progeria From Eiger BiopharmaMedical Dialogues•May 05, 2024•Sentynl Therapeutics, Zokinvy, Eiger BioPharmaceuticals
•
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticalsPR Newswire•May 04, 2024•Sentynl Therapeutics, Eiger BioPharmaceuticals
•
•
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY (Fosdenopterin) for the Treatment of MoCD Type ACMOCRO•Aug 11, 2022•BridgeBio, Sentynl Therapeutics, Medison Pharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Sentynl Therapeutics
Explore our recently published companies
- Medibios - Mumbai based, 1995 founded, Unfunded company
- Om Biomedic - Mumbai based, 2005 founded, Unfunded company
- POA Pharma - Gothenburg based, 2011 founded, Acquired company
- Jonas Pharmaceuticals - Ambala based, 2014 founded, Unfunded company
- Syndicate Life Sciences - Hisar based, 2010 founded, Unfunded company
- Verus Pharmaceuticals - Langfang based, 2002 founded, Deadpooled company
